
Sign up to save your podcasts
Or


The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).
By Howard (Jack) West, MDThe immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).